| 1. |
|
|
| 2. |
- Abramson, JS, et al.
(författare)
-
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study
- 2023
-
Ingår i: Blood. - : American Society of Hematology. - 1528-0020 .- 0006-4971. ; 141:14, s. 1675-1684
-
Tidskriftsartikel (refereegranskat)abstract
- This global, phase 3 study compared lisocabtagene maraleucel (liso-cel) with standard of care (SOC) as second-line therapy for primary refractory or early relapsed (≤12 months) large B-cell lymphoma (LBCL). Adults eligible for autologous stem cell transplantation (ASCT) were randomized 1:1 to liso-cel (100×106 CAR+ T cells) or SOC (3 cycles of platinum-based immunochemotherapy followed by high-dose chemotherapy and ASCT in responders). The primary end point was event-free survival (EFS) by independent review. A total of 184 patients were randomized. In this primary analysis with a median follow-up of 17.5 months, median EFS was not reached (NR) for liso-cel versus 2.4 months for SOC (hazard ratio [HR] = 0.356; 95% confidence interval [CI]: 0.243‒0.522). Complete response (CR) rate was 74% for liso-cel versus 43% for SOC (P < .0001) and median progression-free survival (PFS) was NR for liso-cel versus 6.2 months for SOC (HR = 0.400; 95% CI: 0.261‒0.615; P < .0001). Median overall survival was NR for liso-cel versus 29.9 months for SOC (HR = 0.724; 95% CI: 0.443‒1.183; P = .0987). When adjusted for crossover from SOC to liso-cel, median overall survival was NR for liso-cel and SOC (HR = 0.415; 95% CI: 0.251‒0.686). Grade 3 cytokine release syndrome and neurological events occurred in 1% and 4% of patients in the liso-cel arm, respectively (no grade 4/5 events). These data show significant improvements in EFS, CR rate, and PFS for liso-cel over SOC and support liso-cel as a preferred second-line treatment compared with SOC in patients with primary refractory or early relapsed LBCL. (ClinicalTrials.gov; NCT03575351.)
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
- Arnason, R. M., et al.
(författare)
-
Distances to Galactic X-ray binaries with Gaia DR2
- 2021
-
Ingår i: Monthly Notices of the Royal Astronomical Society. - : Oxford University Press (OUP). - 0035-8711 .- 1365-2966. ; 502:4, s. 5455-5470
-
Tidskriftsartikel (refereegranskat)abstract
- Precise and accurate measurements of distances to Galactic X-ray binaries (XRBs) reduce uncertainties in the determination of XRB physical parameters. We have cross-matched the XRB catalogues of Liu, van Paradijs & van den Heuvel to the results of Gaia Data Release 2. We identify 86 XRBs with a Gaia candidate counterpart, of which 32 are low-mass X-ray binaries (LMXBs) and 54 are high-mass X-ray binaries (HMXBs). Distances to Gaia candidate counterparts are, on average, consistent with those measured by Hipparcos and radio parallaxes. When compared to distances measured by Gaia candidate counterparts, distances measured using Type I X-ray bursts are systematically larger, suggesting that these bursts reach only 50 percent of the Eddington limit. However, these results are strongly dependent on the prior assumptions used for estimating distance from the Gaia parallax measurements. Comparing positions of Gaia candidate counterparts for XRBs in our sample to positions of spiral arms in the Milky Way, we find that HMXBs exhibit mild preference for being closer to spiral arms; LMXBs exhibit mild preference for being closer to interarm regions. LMXBs do not exhibit any preference for leading or trailing their closest spiral arm. HMXBs exhibit a mild preference for trailing their closest spiral arm. The lack of a strong correlation between HMXBs and spiral arms may be explained by star formation occurring closer to the mid-point of the arms, or a time delay between star formation and HMXB formation manifesting as a spatial separation between HMXBs and the spiral arm where they formed.
|
|
